Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) to Enhance Immunotherapy Against T Cell Non-Hodgkin Lymphoma (NHL): a First-in-human Phase I Clinical Trial

Next Previous
Trial Profile

CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) to Enhance Immunotherapy Against T Cell Non-Hodgkin Lymphoma (NHL): a First-in-human Phase I Clinical Trial

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Viper 101 (Primary)
  • Indications Non-Hodgkin's lymphoma; T-cell lymphoma
  • Focus Adverse reactions; First in man
  • Acronyms VIPER101

Most Recent Events

  • 28 May 2025 According to Vittoria Biotherapeutics media release, trial in progress data from this study will be presented at Society of Clinical Oncology (ASCO) Annual Meeting, being held May 30 -June 3, 2025 in Chicago, Illinois.
  • 19 Dec 2024 According to Vittoria Biotherapeutics media release, announced that in November, the first patient was dosed in this study.
  • 19 Nov 2024 According to a viTToria Biotherapeutics media release, the company has received a $25 million private financing round, which is a $10 million extension to its previous $15 million financing secured in November 2023. The latest round was led by Valley Forge Investment Corporation, with new investments from the Global BioAccess Fund and Hatch Biofund, alongside ongoing support from existing investors Agent Capital, Tellus BioVentures, NYBC Ventures, and the University of Pennsylvania. The funding

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top